Company intelligence / Profile preview
Morphocell Technologies
Laval, Quebec, Canadamorphocell.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
01
Overview
Morphocell has collected compelling preclinical efficacy and safety data for its ReLiver technology, with proof-of-concept studies completed in large animals. The company anticipates entering clinical trials within two years (from 2024).
- Therapeutic areas
- Gastroenterology
- Modalities
- Cell therapyStem cell-derived engineered tissues
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
BioSurfacesCHU Sainte-Justine
Beyond the preview
Go deeper on Morphocell Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Morphocell Technologies.